Drug Approval | June 01, 2023
Lupin receives USFDA approval from Obeticholic Acid Tablets
Obeticholic Acid Tablets had estimated annual sales of US$ 262 million in the U.S. (IQVIA MAT Mar 2023).
Obeticholic Acid Tablets had estimated annual sales of US$ 262 million in the U.S. (IQVIA MAT Mar 2023).
With over 150 leading companies, 300+ topline brands and knowledge-led conference sessions, the event is set to make a grand return to the South
Indian government seeks to promote collaboration with stakeholders and harness potential for achieving growth and development of sector
The Indian pharmaceutical industry includes a network of 3,000 drug companies and 10,500 manufacturing units. It is projected to reach a value of US$ 130 billion by 2030
The acquisition of Medisol is part of Lupin's strategy to expand its presence in the EU
Indoco expects this change in compliance status to pave the way for approvals of ANDAs submitted from this site.
It will help in bringing a significant benefit in compliance of ARV medication in the paediatric HIV treatment
Q4 results was challenging driven by steep fall in CDMO revenues and higher upfront cost of Capex projects and R&D projects
The New State-of-Art OligoPilot 2000 solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial oligonucleotide programs.
Subscribe To Our Newsletter & Stay Updated
